We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+28.21%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.31B
AUM Growth
+$110M
Cap. Flow
-$90.6M
Cap. Flow %
-6.94%
Top 10 Hldgs %
78.43%
Holding
36
New
9
Increased
2
Reduced
10
Closed
5

Top Buys

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$60.5M
2
TGTX icon
TG Therapeutics
TGTX
+$31.6M
3
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$17.9M
4
GYRE icon
Gyre Therapeutics
GYRE
+$12.8M
5
CLSD
Clearside Biomedical
CLSD
+$12.4M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$75.3M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$48.8M
3
IFRX icon
InflaRx
IFRX
+$33.1M
4
KDMN
Kadmon Holdings, Inc.
KDMN
+$22.7M
5
SAGE
Sage Therapeutics
SAGE
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
1
Wave Life Sciences
WVE
$1.12B
$301M 23.08%
7,512,049
– –
ASND icon
2
Ascendis Pharma A/S
ASND
$16.5B
$277M 21.25%
4,240,536
-1,340,154
-24% -$75.3M
AVXS
3
DELISTED
AveXis, Inc. Common Stock
AVXS
$127M 9.74%
1,028,289
-142,989
-12% -$17M
MYOV
4
DELISTED
Myovant Sciences Ltd.
MYOV
$60.2M 4.61%
2,830,455
– –
SAGE
5
DELISTED
Sage Therapeutics
SAGE
$56.9M 4.36%
353,133
-102,040
-22% -$17.3M
IFRX icon
6
InflaRx
IFRX
$243M
$46.7M 3.58%
1,620,653
-1,255,427
-44% -$33.1M
ZGNX
7
DELISTED
Zogenix, Inc.
ZGNX
$45.9M 3.51%
1,145,268
– –
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$37.6M 2.88%
3,933,489
-1,032,024
-21% -$11.1M
SCPH
9
DELISTED
scPharmaceuticals
SCPH
$35.4M 2.71%
2,857,143
– –
ECYT
10
DELISTED
Endocyte, Inc. Common Stock
ECYT
$35.3M 2.7%
3,881,793
+517,145
+15% +$2.85M
TGTX icon
11
TG Therapeutics
TGTX
$8.19B
$35.1M 2.69%
+2,472,344
New +$31.6M
KALA icon
12
KALA BIO
KALA
$12.5M
$33.5M 2.56%
846
– –
BCRX icon
13
BioCryst Pharmaceuticals
BCRX
$2.42B
$33.3M 2.55%
6,984,692
– –
RARX
14
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$20.5M 1.57%
3,851,808
+2,500,000
+185% +$17.9M
SLDB icon
15
Solid Biosciences
SLDB
$792M
$20.2M 1.55%
+179,296
New +$60.5M
APLS
16
DELISTED
Apellis Pharmaceuticals
APLS
$19.9M 1.52%
900,000
– –
CLSD
17
DELISTED
Clearside Biomedical
CLSD
$16.4M 1.25%
+101,667
New +$12.4M
AVEO
18
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$14.7M 1.12%
506,276
– –
KALV
19
DELISTED
KalVista Pharmaceuticals
KALV
$13.7M 1.05%
1,441,070
– –
GYRE icon
20
Gyre Therapeutics
GYRE
$629M
$13.3M 1.02%
+68,656
New +$12.8M
IOVA icon
21
Iovance Biotherapeutics
IOVA
$2.04B
$11.1M 0.85%
+659,059
New +$9.98M
SPRO icon
22
Spero Therapeutics
SPRO
$68.9M
$10.6M 0.81%
741,647
-484,000
-39% -$5.87M
BHVN
23
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$9.37M 0.72%
363,636
-1,633,642
-82% -$48.8M
VKTX icon
24
Viking Therapeutics
VKTX
$3.88B
$8.87M 0.68%
+2,029,396
New +$11.2M
VIRX
25
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$6.72M 0.52%
70,613
-17,868
-20% -$3.06M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, RA Capital Management held 36 positions worth $1.31B, up 9.2% from $1.2B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

RA Capital Management withdrew a net $90.6M in Q1 2018, closing 5 positions and reducing 10 holdings. Its most notable exit was Kadmon Holdings, Inc., an estimated $22.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.

Against the trend, RA Capital Management opened a new position in Solid Biosciences worth $20.2M.

  • RA Capital Management's largest Q1 2018 buy was Solid Biosciences: 179,296 shares worth $20.2M.
  • RA Capital Management added most to Ra Pharmaceuticals, Inc. Common Stock in Q1 2018, an estimated $17.9M increase.
  • RA Capital Management's biggest Q1 2018 reduction was Ascendis Pharma A/S, cutting an estimated $75.3M.
  • RA Capital Management fully exited Kadmon Holdings, Inc. in Q1 2018, selling an estimated $22.7M.
  • RA Capital Management's ten largest holdings make up 78% of its $1.31B portfolio in Q1 2018.
  • RA Capital Management opened 9 new positions and closed 5 in Q1 2018.
  • RA Capital Management's portfolio value rose 9.2% quarter-over-quarter to $1.31B.

Based on RA Capital Management's 13F filing for Q1 2018, filed 15 May 2018.